These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31501481)

  • 1. TRAF3 regulates the oncogenic proteins Pim2 and c-Myc to restrain survival in normal and malignant B cells.
    Whillock AL; Mambetsariev N; Lin WW; Stunz LL; Bishop GA
    Sci Rep; 2019 Sep; 9(1):12884. PubMed ID: 31501481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma.
    Edwards SK; Moore CR; Liu Y; Grewal S; Covey LR; Xie P
    BMC Cancer; 2013 Oct; 13():481. PubMed ID: 24131623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
    Kreuz S; Holmes KB; Tooze RM; Lefevre PF
    Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TNF receptor-associated factor 3 restrains B-cell receptor signaling in normal and malignant B cells.
    Whillock AL; Ybarra TK; Bishop GA
    J Biol Chem; 2021; 296():100465. PubMed ID: 33639170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRAF3 deficiency promotes metabolic reprogramming in B cells.
    Mambetsariev N; Lin WW; Wallis AM; Stunz LL; Bishop GA
    Sci Rep; 2016 Oct; 6():35349. PubMed ID: 27752131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas.
    Forshell LP; Li Y; Forshell TZ; Rudelius M; Nilsson L; Keller U; Nilsson J
    Oncotarget; 2011 Jun; 2(6):448-60. PubMed ID: 21646687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylation of USP27X by PIM2 promotes glycolysis and breast cancer progression via deubiquitylation of MYC.
    Han X; Ren C; Lu C; Jiang A; Wang X; Liu L; Yu Z
    Oncogene; 2024 Aug; 43(33):2493-2503. PubMed ID: 38969771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
    Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
    Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells.
    Asano J; Nakano A; Oda A; Amou H; Hiasa M; Takeuchi K; Miki H; Nakamura S; Harada T; Fujii S; Kagawa K; Endo I; Yata K; Sakai A; Ozaki S; Matsumoto T; Abe M
    Leukemia; 2011 Jul; 25(7):1182-8. PubMed ID: 21475253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.
    Tabe Y; Kojima K; Yamamoto S; Sekihara K; Matsushita H; Davis RE; Wang Z; Ma W; Ishizawa J; Kazuno S; Kauffman M; Shacham S; Fujimura T; Ueno T; Miida T; Andreeff M
    PLoS One; 2015; 10(9):e0137210. PubMed ID: 26340096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity.
    Fujii S; Nakamura S; Oda A; Miki H; Tenshin H; Teramachi J; Hiasa M; Bat-Erdene A; Maeda Y; Oura M; Takahashi M; Iwasa M; Endo I; Yoshida S; Aihara KI; Kurahashi K; Harada T; Kagawa K; Nakao M; Sano S; Abe M
    Br J Haematol; 2018 Jan; 180(2):246-258. PubMed ID: 29327347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRAF3, ubiquitination, and B-lymphocyte regulation.
    Lin WW; Hostager BS; Bishop GA
    Immunol Rev; 2015 Jul; 266(1):46-55. PubMed ID: 26085206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated Choline Kinase α-Mediated Choline Metabolism Supports the Prolonged Survival of TRAF3-Deficient B Lymphocytes.
    Gokhale S; Lu W; Zhu S; Liu Y; Hart RP; Rabinowitz JD; Xie P
    J Immunol; 2020 Jan; 204(2):459-471. PubMed ID: 31826940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pim-1 kinase stimulates c-Myc-mediated death signaling upstream of caspase-3 (CPP32)-like protease activation.
    Mochizuki T; Kitanaka C; Noguchi K; Sugiyama A; Kagaya S; Chi S; Asai A; Kuchino Y
    Oncogene; 1997 Sep; 15(12):1471-80. PubMed ID: 9333023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutated in colorectal cancer (MCC) is a novel oncogene in B lymphocytes.
    Edwards SK; Baron J; Moore CR; Liu Y; Perlman DH; Hart RP; Xie P
    J Hematol Oncol; 2014 Sep; 7():56. PubMed ID: 25200342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear TRAF3 is a negative regulator of CREB in B cells.
    Mambetsariev N; Lin WW; Stunz LL; Hanson BM; Hildebrand JM; Bishop GA
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):1032-7. PubMed ID: 26755589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRAF3 as a Multifaceted Regulator of B Lymphocyte Survival and Activation.
    Bishop GA; Stunz LL; Hostager BS
    Front Immunol; 2018; 9():2161. PubMed ID: 30319624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis.
    Shirogane T; Fukada T; Muller JM; Shima DT; Hibi M; Hirano T
    Immunity; 1999 Dec; 11(6):709-19. PubMed ID: 10626893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signaling mechanisms of bortezomib in TRAF3-deficient mouse B lymphoma and human multiple myeloma cells.
    Edwards SK; Han Y; Liu Y; Kreider BZ; Liu Y; Grewal S; Desai A; Baron J; Moore CR; Luo C; Xie P
    Leuk Res; 2016 Feb; 41():85-95. PubMed ID: 26740054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
    Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
    Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.